Gilead Stock News

SDOG: ETF With A Simple And Sensible Strategy, But Average Result.

Investors' focus is likely to be on Gilead's (GILD) HIV franchise performance and oncology sales when the company reports its first-quarter 2023 results.

The "Halftime Report" traders give their top picks to watch for the second half.

High volatility means higher-than-normal option premiums, which can be great for option sellers. The post Get Income On Gilead Stock, Or Buy It At A Discount With This Option Trade appeared first on I

Strong quantitative screens will show investors a variety of growth stocks to buy. For example, StockRover is a screening service that scores stocks on three key metrics.

Gilead (GILD) has an impressive earnings surprise history and currently possesses the right combination of the two key ingredients for a likely beat in its next quarterly report.

AbbVie faces near-term challenges but has solid long-term prospects plus an especially attractive dividend. Gilead Sciences' strong free cash flow should enable the company to continue raising its div

Gilead is predicting increased earnings per share this year. The company has had several key FDA approvals in recent months.

The system is clearly broken, and has been for a while; however, I could find comfort in one thing, my dividends. Four figures in a month is a win in my book. Earning $1,893.81 represents 12.6% year o

Gilead Sciences, Inc. ended 2022 on a solid note. The 2023 guidance (ex-Covid-19 contribution) feels a touch light.

Gilead Sciences, Microsoft, and Apple are all leaders in their respective industries and markets. These blue-chip companies have increased their dividends at a decent clip in the past few years.

The following is a dividend portfolio strategy for large caps that score the highest amongst Joel Greenblatt's Magic Formula screener. The list follows large caps that have dividends.

Gilead has multiple growth opportunities in oncology and HIV that can make it a great long-term buy. The company consistently posts strong profit margins and generates billions in free cash flow.

Our 3-step process focuses on wide-moat stocks (as per Morningstar's rating). We are only interested in those targets that are attractively valued in historical comparison.

Blue chip dividend stocks rarely trade at a discount. Gilead Sciences and Pfizer are two exceptions to this general rule of thumb.